Abstract
Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibited a 10-fold increase in serum levels of transaminases, followed by a rapid decrease after HCQ was withdrawn. Considering the significantly increased use of HCQ during the COVID-19 pandemic, this case alerts us to the potential for HCQ to be associated with hepatotoxicity and the need to monitor liver function during HCQ therapy.
MeSH terms
-
Adult
-
Alanine Transaminase / blood
-
Aspartate Aminotransferases / blood
-
Azithromycin / therapeutic use
-
Betacoronavirus / drug effects
-
Betacoronavirus / isolation & purification
-
Betacoronavirus / pathogenicity*
-
COVID-19
-
Coronavirus Infections / diagnostic imaging
-
Coronavirus Infections / immunology
-
Coronavirus Infections / pathology
-
Coronavirus Infections / therapy*
-
Female
-
Humans
-
Hydroxychloroquine / administration & dosage
-
Hydroxychloroquine / adverse effects*
-
Liver / diagnostic imaging
-
Liver / drug effects*
-
Liver / pathology
-
Liver / virology
-
Lung / diagnostic imaging
-
Lung / drug effects
-
Lung / pathology
-
Lung / virology
-
Pandemics
-
Piperacillin, Tazobactam Drug Combination / therapeutic use
-
Pneumonia, Viral / diagnostic imaging
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / pathology
-
Pneumonia, Viral / therapy*
-
Respiration, Artificial
-
Reverse Transcriptase Polymerase Chain Reaction
-
SARS-CoV-2
-
Tomography, X-Ray Computed
Substances
-
Piperacillin, Tazobactam Drug Combination
-
Hydroxychloroquine
-
Azithromycin
-
Aspartate Aminotransferases
-
Alanine Transaminase